Clinical Trial Update: Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated daclatasvir (BMS-790052) in combination with standard of care for hepatitis C; the study completed and results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Daclatasvir (daclatasvir)
• Pegylated interferon alfa (pegylated interferon alfa)
• Ribavirin (ribavirin)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatitis C Infection | Phase 2 | Status: COMPLETED | Results posted: 2015-10-23